免费看av的,欧美一性一乱一交一视频多男,日韩影院一区,羞羞视频一区二区,国产专区中文字幕,精品免费av,男女av免费观看

關(guān)于我們
研發(fā)服務(wù)
服務(wù)平臺(tái)
客戶中心
新聞資訊
投資者關(guān)系
人力資源
EN
×
EN

  • 業(yè)務(wù)咨詢

    中國：

    Email: marketing@medicilon.com.cn

    業(yè)務(wù)咨詢專線：400-780-8018

    （僅限服務(wù)咨詢，其他事宜請(qǐng)撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在線留言×
點(diǎn)擊切換
Customer Center
客戶中心
Jun 28,2023
索拉非尼的無定形固體分散體用于開發(fā)改良型口服生物利用度高的速釋片劑，本研究中PK實(shí)驗(yàn)通過美迪西進(jìn)行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar?. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar? tablets was performed by Medicilon.
查看更多
索拉非尼的無定形固體分散體用于開發(fā)改良型口服生物利用度高的速釋片劑，本研究中PK實(shí)驗(yàn)通過美迪西進(jìn)行
Jun 28,2023
TAK-931是一種高特異性CDC7抑制劑，具有抗腫瘤功效，本研究中體內(nèi)藥效實(shí)驗(yàn)通過美迪西進(jìn)行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
查看更多
TAK-931是一種高特異性CDC7抑制劑，具有抗腫瘤功效，本研究中體內(nèi)藥效實(shí)驗(yàn)通過美迪西進(jìn)行
Jun 28,2023
GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過美迪西合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過美迪西合成
Jun 28,2023
QF-036是一種高效的HIV-1抑制劑，具有良好的和藥代動(dòng)力學(xué)特性，PK研究通過美迪西進(jìn)行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
查看更多
QF-036是一種高效的HIV-1抑制劑，具有良好的和藥代動(dòng)力學(xué)特性，PK研究通過美迪西進(jìn)行
Jun 28,2023
設(shè)計(jì)合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑制劑，PK研究均通過美迪西進(jìn)行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
查看更多
設(shè)計(jì)合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑制劑，PK研究均通過美迪西進(jìn)行
Jun 28,2023
TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過美迪西進(jìn)行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
查看更多
TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過美迪西進(jìn)行
Jun 28,2023
SKLB-197是一種有效且高度選擇性的ATR抑制劑，PK研究通過美迪西進(jìn)行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
SKLB-197是一種有效且高度選擇性的ATR抑制劑，PK研究通過美迪西進(jìn)行
Jun 28,2023
H11-HLE是一種工具分子，可用于研究Fc在介導(dǎo)免疫檢查點(diǎn)治療中的作用，具有抗腫瘤功效
Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.
查看更多
H11-HLE是一種工具分子，可用于研究Fc在介導(dǎo)免疫檢查點(diǎn)治療中的作用，具有抗腫瘤功效
Jun 28,2023
JND003是一種新型選擇性ERRα激動(dòng)劑，可緩解非酒精性脂肪肝和胰島素抵抗，PK和組織分布測定通過美迪西進(jìn)行
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD.
查看更多
JND003是一種新型選擇性ERRα激動(dòng)劑，可緩解非酒精性脂肪肝和胰島素抵抗，PK和組織分布測定通過美迪西進(jìn)行
Jun 28,2023
發(fā)現(xiàn)用于局部治療牛皮癬的新型PDE4抑制劑，小鼠、大鼠和人肝微粒體的代謝穩(wěn)定性實(shí)驗(yàn)通過美迪西測定
Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and PDE4 is an effective target for the treatment of inflammatory diseases such as psoriasis.
查看更多
發(fā)現(xiàn)用于局部治療牛皮癬的新型PDE4抑制劑，小鼠、大鼠和人肝微粒體的代謝穩(wěn)定性實(shí)驗(yàn)通過美迪西測定
×
搜索驗(yàn)證
點(diǎn)擊切換